Aadi Bioscience, Inc. ( (WHWK) ) has released its Q1 earnings. Here is a breakdown of the information Aadi Bioscience, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Whitehawk Therapeutics, Inc. is an oncology therapeutics company focused on developing advanced ADC cancer treatments by leveraging novel tumor targeting technologies. In its latest earnings report, the company highlighted significant financial and strategic progress, including a substantial increase in cash reserves and a successful divestiture. Key financial metrics from the first quarter of 2025 include a net income of $73 million, largely driven by a gain from the sale of its subsidiary, and a total revenue of $7.1 million. The company’s cash position was notably strengthened to $231.1 million, up from $47.2 million at the end of 2024, providing a runway into 2028. Strategically, Whitehawk completed a $100 million PIPE financing and divested its Aadi Subsidiary to Kaken Pharmaceuticals for $102.4 million. Looking ahead, Whitehawk Therapeutics remains focused on advancing its ADC portfolio, with plans to bring its assets to IND by mid-2026, reflecting a confident outlook on its strategic direction and financial health.